US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed
Name
/
Code
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
Zhihui Mining
02546.HK
Diversified Metals & Minerals 4.1-4.51 1,000 4,555.48 2025/12/16 2025/12/18 2025/12/19
CiDi
03881.HK
Advanced hardware and software 263 10 2,656.52 2025/12/16 2025/12/18 2025/12/19
B&K Corp-B
02396.HK
Biotechnology - Pharmaceuticals 38.2-51 200 10,302.88 2025/12/17 2025/12/19 2025/12/22
BenQ BM Holding
02581.HK
Health Care Services 9.34-11.68 500 5,898.90 2025/12/17 2025/12/19 2025/12/22
Nanhua Futures
02691.HK
Investment Banking & Brokerage 12-16 500 8,080.68 2025/12/17 2025/12/19 2025/12/22
Impression Dahongpao
02695.HK
Movies & Entertainment 3.47-4.1 1,000 4,141.35 2025/12/17 2025/12/19 2025/12/22
Nuobikan
02635.HK
Advanced hardware and software 80-106 50 5,353.45 2025/12/18 2025/12/22 2025/12/23
QingSong Health
02661.HK
Health Care Services 22.68 200 4,581.75 2025/12/18 2025/12/22 2025/12/23
Hanx Bio-B
03378.HK
Biotechnology - Pharmaceuticals 28-32 100 3,232.27 2025/12/18 2025/12/22 2025/12/23
Summary
We are a biotech company, with in-house expertise and experience in structural biology, translational medicine and clinical development. Since 2016, we have developed a product pipeline comprising of one Core Product and nine other pipeline candidates, which are (i) three clinical stage drug candidates focused on oncology, including our Core Product HX009 and Key Products HX301 and HX044; and (ii) seven preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. Prior to the Track Record Period, we also developed HX008, which was transferred to a biopharmaceutical company focusing on oncology therapeutics.

Our Core Product HX009 is a bifunctional anti-PD-1 (an immune checkpoint receptor) antibody SIRP fusion protein developed in-house. During the Track Record Period and up to the Latest Practicable Date, we have completed the Phase I clinical trial of HX009 in Australia and China. We are currently conducting three clinical programs for HX009 in China, namely, (i) the HX009-I-01 China Study (Phase Ib) for treatment of advanced melanoma, (ii) the HX009-II-02 China Study (Phase I/II) for treatment of relapsed/refractory Epstein-Barr virus positive non-Hodgkin lymphoma, and (iii) the HX009-II-05 China Study (Phase IIa) for treatment of advanced biliary tract cancer. We also obtained the NMPA approval in February 2025 for a combination study of HX009 with trastuzumab in patients with advanced triple-negative breast cancer, and we expect the first patient enrollment for this combination study to be in 2026.

As of the Latest Practicable Date, we also have two Key Products, namely HX301 and HX044, which are in the clinical stage, focusing on the treatment of cancer. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as CSF1R, ARK5, FLT-3, and CDK4/6. We have completed the Phase I clinical study of HX301 under its NMPA approval and are currently conducting the Phase II clinical study of HX301 in combination with temozolomide for treatment of glioblastoma in China. HX044 is a novel bifunctional anti-CTLA-4 (an immune checkpoint receptor) antibody SIRP fusion protein, which was created to enhance the CTLA-4-targeting efficacy. We are currently conducting the Phase I/IIa clinical studies of HX044 for treatment of advanced solid tumor malignancies in Australia and China.

Through the discovery, development and commercialization of precision therapies in cancers and autoimmune diseases, we are committed to developing next-generation immunotherapeutics ultimately to help patients with unmet medical needs in global market.

THERE IS NO ASSURANCE THAT WE WILL ULTIMATELY BE ABLE TO DEVELOP AND MARKET OUR CORE PRODUCT OR ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY.



Source: Hanx Bio-B (03378) Prospectus (IPO Date : 2025/12/15)
Listing Market MAIN
Industry Biotechnology - Pharmaceuticals
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders Zhang Faming (Total share: 55.89%); (H share: 55.89%)
Caizhang Vision Limited (Total share: 13.06%); (H share: 13.06%)
Yu Zhihua (Total share: 10.76%); (H share: 10.76%)
Directors Zhang Faming (Chairman and Executive Director)
Liu Min (Chief Operating Officer and Deputy General Manager and Executive Director)
Henry Qixiang Li (General Manager and Chief Executive Officer and Chief Scientific Officer and Executive Director)
Li Jian (Non-Executive Director)
Xiao Jieyu (Non-Executive Director)
. Zhang Qiongguang (Independent Non-Executive Director)
Bi Honggang (Independent Non-Executive Director)
Chen Qifeng (Independent Non-Executive Director)
Wong Sai Hung (Independent Non-Executive Director)
Company Secretary Li Kin Wai
Zhang Hui
Principal Bankers China Merchants Bank
Solicitors Jingtian & Gongcheng LLP
Jingtian & Gongcheng
Auditors Ernst & Young
Registered Office 3/F, Building 2W Science Park Avenue Hong Kong Science Park Shatin New Territories Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.hanxbio.com
Email Address info@hanxbio.com
Tel No (86 027) 6552-4978
Fax No
 
SITEMAP
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.